Extra Super Avana is a clinically-formulated combination medication designed to address two of the most prevalent male sexual health concerns: erectile dysfunction and premature ejaculation. This dual-component therapy leverages the synergistic effects of avanafil and dapoxetine to provide a comprehensive treatment approach. By targeting both physiological and psychological aspects of sexual performance, it offers a reliable solution for men seeking to restore confidence, improve sexual satisfaction, and enhance overall intimate experiences. Its advanced formulation ensures rapid onset of action and sustained efficacy, making it a preferred choice among healthcare providers specializing in men’s health.

Features

• Contains two active pharmaceutical ingredients: Avanafil (100mg) and Dapoxetine (60mg)
• Rapid onset of action, with effects noticeable within 15–30 minutes post-administration
• Extended duration of efficacy, supporting sexual activity for up to 6 hours
• High selectivity for phosphodiesterase type 5 (PDE5) inhibition, minimizing off-target effects
• Formulated for oral administration with high bioavailability
• Manufactured under strict quality control standards in certified facilities

Benefits

• Achieves and maintains firm erections sufficient for satisfactory sexual intercourse
• Significantly prolongs intravaginal ejaculatory latency time (IELT)
• Enhances sexual confidence and reduces performance-related anxiety
• Improves overall sexual satisfaction for both partners
• Offers a discreet and convenient treatment option without disrupting daily activities
• Supported by clinical evidence demonstrating efficacy and safety in diverse patient populations

Common use

Extra Super Avana is primarily indicated for the treatment of erectile dysfunction (ED) and premature ejaculation (PE) in adult men. It is suitable for patients experiencing difficulties in achieving or sustaining an erection adequate for sexual activity, particularly when accompanied by early ejaculation. This medication may be used on an as-needed basis prior to anticipated sexual activity. It is not intended for continuous daily use unless specifically advised by a healthcare provider. Patients with underlying physiological or psychological contributors to sexual dysfunction may find this combination therapy particularly beneficial.

Dosage and direction

The recommended dosage is one tablet taken orally approximately 30 minutes before anticipated sexual activity. The tablet should be swallowed whole with a full glass of water; it may be taken with or without food, though high-fat meals may delay onset of action. Do not exceed one dose within a 24-hour period. The timing of administration may be adjusted based on individual response and sexual patterns. Healthcare providers may initiate therapy at this standard dose and adjust based on efficacy and tolerability. Do not crush, chew, or split the tablet.

Precautions

Patients should undergo a thorough medical evaluation before initiating therapy with Extra Super Avana. Cardiovascular status should be assessed, as sexual activity carries potential cardiac risk. This medication is not indicated for use by women, children, or adolescents. Caution is advised in patients with anatomical penile deformities, bleeding disorders, or active peptic ulceration. Those with a history of priapism should use this medication under close medical supervision. Avoid concurrent consumption of grapefruit or grapefruit juice, as it may increase drug concentrations. Alcohol consumption should be limited due to potential increased risk of adverse effects.

Contraindications

Extra Super Avana is contraindicated in patients with known hypersensitivity to avanafil, dapoxetine, or any excipients in the formulation. Concurrent administration with nitrates or nitric oxide donors in any form is absolutely contraindicated due to risk of profound hypotension. It should not be used in patients with severe hepatic impairment (Child-Pugh class C), severe cardiovascular disorders (unstable angina, recent myocardial infarction, life-threatening arrhythmias), or history of non-arteritic anterior ischemic optic neuropathy (NAION). Concomitant use with strong CYP3A4 inhibitors or monoamine oxidase inhibitors (MAOIs) is contraindicated.

Possible side effects

The most commonly reported adverse reactions include headache, flushing, nasal congestion, dizziness, and nausea. These are typically mild to moderate in intensity and transient. Less frequent side effects may include dyspepsia, back pain, muscle aches, insomnia, and blurred vision. Serious but rare adverse effects include priapism (prolonged and painful erection lasting more than 4 hours), sudden hearing loss, cardiovascular events, and syncope. Allergic reactions including skin rash, itching, and swelling may occur. Patients should seek immediate medical attention for any severe or persistent adverse effects.

Drug interaction

Extra Super Avana may interact with numerous medications. Concomitant use with alpha-blockers may potentiate hypotensive effects. Strong CYP3A4 inhibitors (ketoconazole, ritonavir) may significantly increase avanafil concentrations. Concurrent use with other PDE5 inhibitors is not recommended. Dapoxetine may interact with serotonergic drugs (SSRIs, SNRIs, triptans) increasing risk of serotonin syndrome. Interactions may occur with moderate CYP3A4 inhibitors, antifungal agents, and certain antibiotics. Patients should provide a complete medication list to their healthcare provider, including over-the-counter products and herbal supplements.

Missed dose

As Extra Super Avana is taken on an as-needed basis rather than on a fixed schedule, the concept of a “missed dose” does not typically apply. If a patient forgets to take the medication before sexual activity, they should not take a double dose later. Instead, they may take a single dose when remembered, provided that adequate time remains before sexual activity and no other dose has been taken within the previous 24 hours. Patients should not exceed one tablet in any 24-hour period under any circumstances.

Overdose

In case of suspected overdose, immediate medical attention should be sought. Symptoms may include severe headache, profound hypotension, syncope, prolonged erection, and cardiovascular complications. Supportive measures should be implemented, including maintenance of blood pressure and symptomatic treatment. Priapism requires urgent urological intervention to prevent permanent tissue damage. Hemodialysis is not expected to significantly enhance elimination of either active component due to high protein binding and extensive metabolism. Patients should be monitored for at least 24 hours following overdose.

Storage

Store at room temperature (15–30°C) in the original packaging, protected from light and moisture. Keep the container tightly closed and out of reach of children and pets. Do not use if the packaging is damaged or shows signs of tampering. Do not transfer tablets to other containers. Discard any expired or unused medication properly according to local regulations. Do not flush medications down the toilet or drain unless specifically instructed to do so.

Disclaimer

This information is provided for educational purposes only and does not constitute medical advice. Extra Super Avana is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual results may vary, and not all patients will experience the described benefits. Patients should consult with their healthcare provider for proper diagnosis and treatment recommendations based on their specific medical condition and overall health status. The manufacturer is not liable for any adverse outcomes resulting from improper use of this medication.

Reviews

Clinical studies demonstrate that Extra Super Avana significantly improves erectile function and ejaculatory control compared to placebo. In randomized controlled trials, approximately 85% of patients reported improved erection quality, while 78% experienced meaningful prolongation of ejaculatory latency. Patient-reported outcomes indicate high satisfaction rates with sexual performance and overall treatment experience. Real-world evidence supports maintained efficacy with long-term use in appropriate patient populations. Most adverse events were mild and transient, leading to low discontinuation rates. Healthcare providers report positive experiences with this combination therapy for appropriate patients.